At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Intravitreal Aflibercept Injection +1 moredrug
Likely dose
Intravitreal Aflibercept Injection 2.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravitreal Aflibercept Injection as a Surgical Adjuvant in Severe Proliferative Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating Intravitreal Aflibercept Injection and Standard Vitrectomy for Vitreous Hemorrhage. Completed, enrolled 12 participants across 1 site.
Detailed Summary
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreous Hemorrhage
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionFeb 2014
Study CompletionNov 2015
TodayJul 2026
First PostedMar 6, 2013
Enrollment StartMar 1, 2013
Primary CompletionFeb 1, 2014
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.3 years ago
Interventions
Intravitreal Aflibercept Injectiondrug
One time 2.0mg aflibercept injection, following pars plana vitrectomy.
Standard Vitrectomyother
Surgical intervention